HighLife raises EUR 80 million in funding round backed by VI Partners

• HighLife raised more than USD 90 million (EUR 80 million) in a private financing round to fund a US pivotal study.
• Proceeds also target faster commercial expansion in Europe following CE Mark clearance for its transcatheter mitral valve replacement system.
• Round was co-led by Andera Partners, Sofinnova Partners, Supernova Invest, Mérieux Equity Partners; VI Partners joined as an existing investor.
• HighLife develops percutaneous valve-in-ring technology for severe mitral regurgitation in patients unsuitable for surgery or edge-to-edge repair.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VI Partners Ltd. published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.